Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

This is a phase III, randomized, open-label, multi-center study to assess the efficacy of treatment intensification with docetaxel plus apalutamide and ADT, assessed by event-free survival, in patients with mHSPC who do not achieve deep PSA response (≤0,2 ng/ml or PSA90 response in combination with a PSA ≤ 4 ng/ml) after initial treatment with apalutamide and ADT. A non-deep PSA response is defined as PSA \> 0.2 ng/ml in combination with a PSA response \< 90%, or a PSA response ≥90% in combination with a PSA \> 4 ng/ml.

Trial Details

NCT ID
NCT07333066
Phase
PHASE3
Sponsor
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Status
RECRUITING
Cancer Type
Hormone-Sensitive Prostate Cancer
Interventions
  • Apalutamide (Erleada™) 60 mg or 240 mg tablets
  • Docetaxel
Locations (sample)
  • Bayonne, France|43.49316,-1.473
  • Bordeaux, France|44.84124,-0.58046
  • Brest, France|48.39029,-4.48628
  • Créteil, France|48.79266,2.46569
  • Grenoble, France|45.17869,5.71479

Key Eligibility Criteria

  • Written informed consent. Each patient must sign an informed consent form (ICF) indicating that he understands the purpose of and procedures, requi…
  • Patient must be a man ≥18 years of age.
  • Histologically or cytologically confirmed adenocarcinoma of prostate.
  • Metastatic hormone-sensitive prostate cancer.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hormone-Sensitive Prostate Cancer Trials on Trialify →